RT Journal Article
SR Electronic
T1 The SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: analysis of high-throughput genetic, epigenetic, and gene expression studies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.23.21254175
DO 10.1101/2021.03.23.21254175
A1 Malato, João
A1 Sotzny, Franziska
A1 Bauer, Sandra
A1 Freitag, Helma
A1 Fonseca, André
A1 Grabowska, Anna D
A1 Graça, Luís
A1 Cordeiro, Clara
A1 Nacul, Luís
A1 Lacerda, Eliana M
A1 Castro-Marrero, Jesus
A1 Scheibenbogen, Carmen
A1 Westermeier, Francisco
A1 Sepúlveda, Nuno
YR 2021
UL http://medrxiv.org/content/early/2021/03/24/2021.03.23.21254175.abstract
AB Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) show specific epigenetic and gene expression signatures of the disease. However, it is unknown whether these signatures in ME/CFS include abnormal levels of the human angiotensin-converting enzyme ACE and ACE2, the latter being the main receptor described for host-cell invasion by SARS-CoV-2. To investigate that, we first reviewed published case-control genome-wide association studies based on single nucleotide polymorphism data, case-control epigenome-wide association studies based on DNA methylation data, and case-control gene expression studies based on microarray data. From these published studies, we did not find any evidence for a difference between patients with ME/CFS and healthy controls in terms of genetic variation, DNA methylation, and gene expression levels of ACE and ACE2. In line with this evidence, the analysis of a new data set on the ACE/ACE2 gene expression in peripheral blood mononuclear cells did not find any differences between a female cohort of 37 patients and 34 age-matched healthy controls. Future studies should be conducted to extend this investigation to other potential receptors used by SARS-CoV-2. These studies will help researchers and clinicians to better assess the health risk imposed by this virus when infecting patients with this debilitating disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJM and AF were fully funded by Fundação para a Ciência e Tecnologia, Portugal (ref.grant: SFRH/BD/149758/2019 and SFRH/BD/147629/2019, respectively). NS and CC were partially funded by Fundação para a Ciência e a Tecnologia, Portugal (ref. grant: UIDB/00006/2020). LN and EML acknowledge the funding from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH -Award Number: R01AI103629), and from the ME Association (Award number: PF8947) for their studies on ME/CFS. The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funding agencies did not have any role in the designing, data collection, data analysis, interpretation or writing-up the present manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol of the German ME/CFS cohort study was approved by the Ethics Committee of Charité-Universitätsmedizin Berlin in accordance with the 1964 Declaration of Helsinki and its later amendments (reference number EA2/067/20). All patients and healthy controls recruited from staff gave written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData sets from epigenetic-wide and gene expression studies are publicly available at the NCBI GEO data repository. The data set from the German cohort is available from Prof Carmen Scheibenbogen upon request. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE59489 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE93266 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE156792 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111183 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14577 ACE and ACE2Human angiotensin-converting enzymes 1 and 2, respectivelyADAM17A disintegrin and metallopeptidase domain 17 proteinCCCCanadian Consensus Criteria1994 CDC/Fukuda1994 Centers for Diseases Control and Prevention CriteriaCOVID-19Coronavirus disease 2019DPP4Dipeptidyl peptidase-4EWASepigenome-wide association study or (studies)GEOGene Expression OmnibusGESgene expression study (or studies)GWASGenome-wide association study (or studies)ME/CFSMyalgic encephalomyelitis/Chronic Fatigue SyndromeMERSmiddle east respiratory syndromeNCBINational Centre for Biotechnology InformationPBMCperipheral blood mononuclear cellS1viral spike glycoproteinROCreceiver operating characteristicSARS-CoV-1severe acute respiratory syndrome coronavirus-1SARS-CoV-1/-2severe acute respiratory syndrome coronavirus-1/-2SNPsingle nucleotide polymorphismTMPRSS2transmembrane protease serine 2.